Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.
NCT00421252 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. As of 21 Nov 2026, it was terminated. It studies Clopidogrel in Bleeding, Coronary Artery Disease and 1 more condition. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2007 and a primary completion date of 30 Nov 2007.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00421252 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Beth Israel Deaconess Medical Center |
| Enrollment | 18 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Bleeding, Coronary Artery Disease and Myocardial Ischemia |
| Drugs | Clopidogrel |
| Start | 31 Jan 2007 |
| Primary completion | 30 Nov 2007 |
| Study completion | 31 Jan 2008 |
| Last update posted | 14 Apr 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joseph P Carrozza, MD
Beth Israel Deaconess Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beth Israel Deaconess Medical Center
Boston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00421252
Each answer restates registry values shown on this page.
What is NCT00421252?
NCT00421252 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. It studies Clopidogrel in Bleeding, Coronary Artery Disease and 1 more condition.
Who leads NCT00421252?
The registry names Joseph P Carrozza, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.
Where does NCT00421252 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00421252 study?
The registered drug and biological interventions are Clopidogrel.
When did NCT00421252 end?
The registry lists a primary completion date of 30 Nov 2007 and a study completion date of 31 Jan 2008. The sponsor last updated the record on 14 Apr 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.